In September of the same year, Dizal Pharm Co Ltd announced the results of the Chinese registered clinical trial of sunvozertinib in the treatment of EGFR exon 20 insertion (Exon20ins) mutant advanced NSCLC at the European Society of Internal Oncology (ESMO) Congress. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.